Shanghai Bao Pharmaceuticals Co., Ltd.

Shanghai Bao Pharmaceuticals Co., Ltd. operates as a clinical-stage biotechnology company. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products include KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology; BJ007, a SC administered ceftriaxone sodium for the treatment of bacterial infections; and KJ101, a recombinant human chymotrypsin developed through synthetic biology. The company also develops drug design platform, chassis cell engineering platform, and comprehensive bioprocessing platform. The company sells its products under the Bao Pharma brand name. Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.